Home › NDC Lookup › RxCUI directory › RxCUI 2642350

Miglustat 100 MG Oral Capsule [Yargesa] — RxCUI 2642350

RxNorm drug concept · Semantic branded drug
RxCUI 2642350 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2642350
Official nameMiglustat 100 MG Oral Capsule [Yargesa]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asYargesa 100 MG Oral Capsule
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Miglustat: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Miglustat (also sold as Yargesa or Zavesca) treats adults with mild to moderate type 1 Gaucher disease — a rare condition where a missing enzyme lets a fatty substance build up in...
  • For type 1 Gaucher disease, miglustat capsules are generally taken three times a day. You can take them with or without food — food slows absorption slightly but doesn't change how...
  • How should I take my miglustat capsules?
  • Yes — diarrhea is very common with miglustat, affecting up to 89% of patients in studies. It happens because miglustat interferes with the digestion of certain sugars in your gut....
📖 Read our full Miglustat guide →

🕸️ Concept Web — How Miglustat 100 MG Oral Capsule [Yargesa] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Miglustat 100 MG Oral Capsule [Yargesa] RxCUI 2642350

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Miglustat 402316
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Yargesa 2642345
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Miglustat Oral Capsule 402347
    • Miglustat Oral Product 1164725
    • Miglustat Pill 1164726
    • Miglustat Oral Capsule [Yargesa] 2642349
    • Yargesa Oral Product 2642347
    • Yargesa Pill 2642348
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Miglustat 100 MG Oral Capsule SCD · 401938
  • Miglustat 100 MG SCDC · 402346
  • Miglustat Oral Capsule SCDF · 402347
  • Miglustat Oral Product SCDG · 1164725
  • Miglustat Pill SCDG · 1164726

Brand-Name Concepts

  • Miglustat 100 MG [Yargesa] SBDC · 2642346
  • Miglustat Oral Capsule [Yargesa] SBDF · 2642349
  • Yargesa Oral Product SBDG · 2642347
  • Yargesa Pill SBDG · 2642348
  • Yargesa BN · 2642345

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2642350 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
42799-0709-15 1 BLISTER PACK in 1 CARTON (42799-709-15) / 15 CAPSULE in 1... Yargesa Edenbridge Pharmaceuticals LLC. 2023-10-31
Observed labelers: Edenbridge Pharmaceuticals LLC. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.